Article Versions Notes

Jakimovski D, Zakalik K, Awan S, Kavak KS, Pennington P, Hojnacki D, Kolb C, Lizarraga AA, Eckert SP, Sarrosa R, et al. COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. Vaccines. 2022; 10(5):695. https://doi.org/10.3390/vaccines10050695

Jakimovski, Dejan, Karen Zakalik, Samreen Awan, Katelyn S. Kavak, Penny Pennington, David Hojnacki, Channa Kolb, Alexis A. Lizarraga, Svetlana P. Eckert, Rosila Sarrosa, and et al. 2022. "COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections" Vaccines 10, no. 5: 695. https://doi.org/10.3390/vaccines10050695

Jakimovski, D., Zakalik, K., Awan, S., Kavak, K. S., Pennington, P., Hojnacki, D., Kolb, C., Lizarraga, A. A., Eckert, S. P., Sarrosa, R., Vineetha, K., Edwards, K., & Weinstock-Guttman, B. (2022). COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. Vaccines, 10(5), 695. https://doi.org/10.3390/vaccines10050695